AstraZeneca reports mixed late-stage trial results: Claudin 18.2 ADC shows limited success while Ultomiris fails in rare disease

AstraZeneca announced that two of its late-stage clinical programs have delivered disappointing outcomes. The company disclosed the data in a statement released on Monday.

The trial of the Claudin 18.2‑targeting antibody‑drug conjugate in stomach cancer met its primary endpoint, but the results came with a notable caveat that limits the enthusiasm for the product’s commercial potential.

In contrast, the Phase 3 study of Ultomiris in a rare disease indication fell short of expectations, showing subpar efficacy compared with existing therapies.

These setbacks temper AstraZeneca’s earlier optimism about the pipeline and may affect its sales forecasts for the coming years.